Skip to Content

Repligen Corp RGEN

Morningstar Rating
$195.52 +1.53 (0.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RGEN is trading at a 4% premium.
Price
$196.14
Fair Value
$953.12
Uncertainty
Very High
1-Star Price
$418.98
5-Star Price
$923.47
Economic Moat
Gsgxmnr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$193.99
Day Range
$190.80196.34
52-Week Range
$110.45211.13
Bid/Ask
$140.00 / $195.52
Market Cap
$10.90 Bil
Volume/Avg
526,144 / 597,812

Key Statistics

Price/Earnings (Normalized)
94.00
Price/Sales
17.26
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.13%

Company Profile

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Growth
Total Number of Employees
1,783

Comparables

Valuation

Metric
RGEN
MLAB
CYRX
Price/Earnings (Normalized)
94.0029.4528.59
Price/Book Value
5.531.461.71
Price/Sales
17.262.773.68
Price/Cash Flow
89.9413.30145.28
Price/Earnings
RGEN
MLAB
CYRX

Financial Strength

Metric
RGEN
MLAB
CYRX
Quick Ratio
5.541.4511.32
Current Ratio
7.022.6812.23
Interest Coverage
33.870.89−6.71
Quick Ratio
RGEN
MLAB
CYRX

Profitability

Metric
RGEN
MLAB
CYRX
Return on Assets (Normalized)
3.80%1.54%−3.12%
Return on Equity (Normalized)
5.03%2.63%−6.05%
Return on Invested Capital (Normalized)
4.09%2.46%−2.81%
Return on Assets
RGEN
MLAB
CYRX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncLwwr$140.2 Bil
BDX
Becton Dickinson & CoYgfylg$68.0 Bil
ALC
Alcon IncKnyznz$42.4 Bil
CLPBY
Coloplast A/S ADRCpbn$29.9 Bil
WST
West Pharmaceutical Services IncSsbf$26.3 Bil
RMD
ResMed IncVkbst$25.7 Bil
BAX
Baxter International IncHyhnwgd$20.8 Bil
COO
The Cooper Companies IncTfzbwc$20.3 Bil
HOLX
Hologic IncXzydsql$17.3 Bil
TFX
Teleflex IncFhvtz$10.5 Bil

Sponsor Center